Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (scientific article published on 26 December 2015)

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Q27851468

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

Q27851691

Trastuzumab emtansine for HER2-positive advanced breast cancer

Q27851917

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Q27853001

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Q29616112

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Q33827808

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study

Q33855396

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study

Q34641036

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Q35584206

Adjuvant trastuzumab in HER2-positive breast cancer

Q35710898

A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer

Q38070443

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

Q46074968

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial

Q46725373

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

Q47951353

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Q51099066

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Q53158182

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Q53243856

Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy

Q69612813

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

Q70866838

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

trastuzumab

Q412616

P304

page(s)

127-132

P577

publication date

2015-12-26

P1433

published in

Breast Cancer Research and Treatment

Q326085

P1476

title

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

P478

volume

155

Reverse relations

cites work (P2860)

Q47598844	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
Q40159320	Trastuzumab and survival of patients with metastatic breast cancer.
Q92861867	Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis